



Aridis Pharmaceuticals' Novel Antibody Therapy for Hospital-Acquired Pneumonia Selected as a Top Infectious Disease Project to Watch

-- To Present AR-301 at 2014 Therapeutic Area Partnerships Conference --

SAN JOSE, Calif., November 19, 2014 - Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that AR-301, the Company's fully human monoclonal IgG1 antibody specifically targeting *S. aureus* alpha-toxin for the treatment of hospital acquired pneumonia (HAP), was selected as a "Top Project to Watch" in the Infectious Disease category at the upcoming 2014 Therapeutic Area Partnerships conference held in Boston, MA, November 19-21.

AR-301 was selected from among hundreds of compounds by a panel of respected industry experts, based on its likelihood of success as a future product. Many past "Top 10" Projects have gone on to establish successful partnerships, including Rhythm, Trophos, BiPar, Myogen, Sirtris and Kosan.

As a recipient of this honor, Aridis Pharmaceutical's Founder and Chief Executive Officer Vu Truong, Ph.D., was invited to present an overview of the Company's business, highlighting AR-301 as a novel treatment for HAP.

Event:	Therapeutic Area Partnerships Conference
Date:	Thursday, November 20, 2014
Time:	4:10 pm (Eastern Time)
Session:	Track 5 – Infectious Diseases
Location:	Hyatt Regency, Boston, MA

About Aridis Pharmaceuticals, Inc.

Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX[®] and pharmaceutical formulation technologies to produce novel infectious disease focused therapies. Aridis' product pipeline includes AR-301 anti-*Staphylococcus aureus* human monoclonal antibody to treat acute pneumonia; AR-101 anti-*Pseudomonas aeruginosa* LPS human monoclonal antibody; Panaecin[™], a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; Aerucin[™], a broadly reactive monoclonal antibody against *Pseudomonas aeruginosa* initially being developed to treat acute pneumonia; AR-401 anti-*Acinetobacter baumannii* human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of AR-301, AR-101, Panaecin[™], Aerucin[™], AR-401, AR-201, Aridis' proprietary formulation and delivery technologies, about Aridis' strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis' expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis' research and clinical studies and its ability to obtain additional financing. These forward-looking statements represent Aridis' judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com
(212) 375-2664

Amy Wheeler (media)
awheeler@tiberend.com
(212) 827-0020